Open Access Library Journal 2018, Volume 5, e4765 ISSN Online: 2333-9721 ISSN Print: 2333-9705 DOI: 10.4236/oalib.1104765 Aug. 6, 2018 1 Open Access Library Journal Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop©) in Episodic Migraine Prevention: A Multicentric Observational Study Federico Mainardi 1 , Paola Merlo 2 , Ferdinando Maggioni 3 , Giorgio Zanchin 3 , Giorgio Dalla Volta 4* 1 Headache Centre, Neurological Division, SS Giovanni e Paolo Hospital, Venice, Italy 2 Headache Centre of Neurological Division of Gavazzeni Hospital, Bergamo, Italy 3 Headache Centre, Department of Neurosciences, Padua University, Padua, Italy 4 Headache Center of Neurological Unit of Istituto Clinico Città di Brescia, Brescia, Italy Abstract Objective: To verify the efficacy and safety of the new combination of Tana- cetum parthenium 150 mg, 5-hydrossitriptophan (5-HTTP) 20 mg and mag- nesium 185 mg (Aurastop®) in the prophylactic treatment of episodic mi- graine without aura (MO). Methods: Eighty patients suffering from MO for at least 6 months with a monthly frequency of 3 to 8 attacks and 4 to12 head- ache days, were enrolled in this open study and treated with Aurastop twice daily per os for 3 months. The reduction of headache days per month was as- sessed as the primary end-point, while the secondary end-points were: 1) re- duction of the number of MO attacks; 2) reduction of intensity of the pain; 3) reduction of acute treatment drug intake; 4) subjective change of pain inten- sity. Results: All the parameters significantly improved at the end of the ob- servational period of treatment with Aurastop. In more detail: a significant reduction of the number of headache days (from 9.1 ± 2.0 before treatment to 3.2 ± 1.8 post treatment, p < 0.001); number of attacks per month (from 6.0 ± 1.2 to 2.4 ± 1.1, p < 0.001); pain intensity (in a visual analogical scale [VAS]: from 7 ± 1.0 to 3.2 ± 0.7, p < 0.001); number of drug doses for acute treat- ment (triptans, simple analgesics or in combination) assumed by each subject per month (from 9.5 ± 1.8 to 2.2 ± 1.1, p < 0.001). No serious adverse events were observed. Conclusion: Albeit obtained with the limitation of open-trials, our findings suggest that AURASTOP® is a promising approach for migraine prevention; further investigations are required to confirm the safety and effi- cacy of this treatment. How to cite this paper: Mainardi, F., Merlo, P., Maggioni, F., Zanchin, G. and Volta, G.D. ( 2018) Efficacy of a Combination of Tanacetum parthenium, 5-Hydroxy Tryptophan and Magnesium (Aurastop©) in Episodic Migraine Prevention: A Multicentric Observational Study. Open Access Library Journal, 5: e4765. https://doi.org/10.4236/oalib.1104765 Received: July 9, 2018 Accepted: August 3, 2018 Published: August 6, 2018 Copyright © 2018 by authors and Open Access Library Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/ Open Access